Piramal Pharma's Commitment to a Sustainable Future
Piramal Pharma Limited, a prominent player in the global pharmaceutical industry, is focusing on sustainability as a core aspect of its future. Recently, the company received validation from the Science Based Targets initiative (SBTi) for its greenhouse gas (GHG) emission reduction targets. This achievement highlights Piramal Pharma's commitment to adopting sustainable measures and making tangible progress in diminishing its environmental footprint.
Ambitious Sustainability Goals
In line with its sustainability commitment, Piramal Pharma aims to reduce its Scope 1 and 2 GHG emissions by 42% by the end of FY2030, using FY2022 as the starting point. Furthermore, the company has set a goal to lower its Scope 3 GHG emissions, which pertain to emissions from purchased goods and services, energy-related activities, transportation, and product usage, by 25% within the same timeline. This ambitious pledge positions Piramal Pharma among the leading global pharmaceutical companies that recognize the critical importance of sustainable practices.
Leadership Insights
Nandini Piramal, Chairperson of Piramal Pharma Limited, underscored the significance of this initiative, expressing, "Sustainability is at the heart of our business strategy, and the approval from SBTi reinforces our ongoing commitment to reducing our GHG emissions and aligning with global climate action goals." Her comments reflect the broader vision of the company, which is actively developing a detailed Carbon Reduction Plan to amplify its sustainability efforts.
Understanding the Science Based Targets Initiative
The SBTi serves as an essential framework for businesses striving to diminish their GHG emissions. By establishing scientifically-founded guidelines, the initiative defines the necessary reductions to keep global temperature rise limited to well below 1.5°C compared to pre-industrial levels. By teaming up with SBTi, Piramal Pharma aligns itself with other organizations committed to making measurable environmental improvements.
Moving Forward with Piramal Pharma
Piramal Pharma's diverse pharmaceutical offerings and focus on environmental responsibility allow it to prioritize both business growth and a sustainable future for the industry and society. The company operates 17 global development and manufacturing facilities, delivering products to over 100 countries and demonstrating its significant market impact.
Broadening Business Horizons
Piramal Pharma encompasses various segments, including Piramal Pharma Solutions, which functions as an integrated contract development and manufacturing organization, and Piramal Critical Care, dedicated to complex hospital generics. Their strategic collaborations with partner companies, like Abbvie Therapeutics India Private Limited, help solidify their position across multiple therapeutic areas.
Piramal Pharma's Future Plans
As a forward-thinking organization, Piramal Pharma is devoted to evolving its strategies to ensure sustainability remains central to its operations. The leadership at Piramal Pharma understands that although significant progress has been made, the path to true sustainability is continuous and demands ongoing effort.
Frequently Asked Questions
What GHG reduction targets has Piramal Pharma set?
Piramal Pharma aims to cut Scope 1 and 2 GHG emissions by 42% and Scope 3 emissions by 25% by FY2030, using FY2022 as their baseline year.
How does the SBTi support sustainability efforts?
The SBTi enables businesses to establish science-based targets for reducing emissions, offering a structured approach to promote sustainable growth.
Who is Nandini Piramal?
Nandini Piramal serves as the Chairperson of Piramal Pharma Limited, promoting sustainability and environmental responsibility within the company's strategic directions.
Where does Piramal Pharma operate?
Piramal Pharma Limited has a global presence, with development and manufacturing facilities in several countries, and distributes its products to more than 100 markets worldwide.
What segments are part of Piramal Pharma's business?
Piramal Pharma operates in various segments, including contract development, manufacturing, critical care, and consumer healthcare, enhancing its influence in the pharmaceutical industry.
